Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
2025-12-09
Has the American Society of Clinical Oncology made any recommendations concerning the use of cannabinoids as a cancer-directed treatment?
Yes, according to the article 'Integrative Therapies in Cancer Care: An Update on the Guidelines,' "Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial." Also, "clinicians should recommend against use of cannabis and/or cannabinoids in place of cancer- directed treatment." Gowin K, Muminovic M, Zick S, et al. Integrative Therapies in Cancer Care: An Update on the Guidelines. ASCO Educational Book (asco.ord/edbook) Vol 44, Iss 3. Mar 31 2024.
2025-12-08
What is the half life of CBD? How does it compare to the half life of THC?
The half life of CBD is 18-32 hours, which is similar to the half life of THC of 20-30 hours. Both CBD and THC are distributed to fatty tissues and highly perfused organs such as brain, heart, lung, and liver.Page II RL , Allen LA , Kloner RA , Carriker CR , Martel C , Morris AA , Piano MR , Rana JS , Saucedo JF, et al. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association - Originally published5 Aug 2020https://doi.org/10.1161/CIR.0000000000000883Circulation. 2020;142:e131–e152
2025-12-05
Cannabis products purchased at a medical dispensary and over the counter CBD products are not FDA-approved. Does the FDA accept adverse event reports associated with the cannabinoid products?
Yes. "Consumers and healthcare providers can report adverse events associated with cannabis or cannabis-derived products via the FDA’s MedWatch reporting system, either on the FDA website (MedWatch: The FDA Safety Information and Adverse Event Reporting Program webpage) or by phone at 1-800-FDA-1088." https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#:~:text=Consumers%20and%20healthcare%20providers%20can,%2D800%2DFDA%2D1088.
2025-12-04
The anti-platelet agent Clopidogrel (Plavix) becomes active only after it is metabolized by a liver enzyme (CYP2C19) and converted to a thiol metabolite. Does CBD inhibit the activity of CYP2C19? If so, what are the potential clinical consequences?
Yes. "In vitro studies have demonstrated greater than 50% inhibition of CYP2C19 at [CBD] concentrations that would result from use of typical CBD doses of 300 mg to 1,500 mg per day. Because CBD inhibits CYP2C19 at clinically relevant concentrations, this interaction may compromise clopidogrel’s antiplatelet activity, thereby increasing risk for CV (cardiovascular) events. It may be beneficial to consider close monitoring of signs and symptoms of diminished clopidogrel activity or consider an alternative agent such as prasugrel or ticagrelor, which do not rely on CYP2C19 for activation, particularly in those who have undergone recent deployment of drug-eluting stents." Jones T, Costello A, Cadiz C. Cannabinoids and drug-drug interactions with CV medications. Cardiology Today. Sept 2022.
2025-12-03
Multiple Sclerosis (MS) is a qualifying condition for participation in many state medical cannabis programs. What are the symptoms MS patients hope to treat by consuming cannabinoid-based products? What are the common side effects they encounter?
According to a survey of MS patients in Canada, self-medication with THC-containing cannabinoids appears to be widespread among patients with multiple sclerosis. Target symptoms typically include sleep disturbances, pain, and spasticity, with the most commonly reported side effects being drowsiness, emotional flattening, and difficulty concentrating.Sanatarossa, So, Smyth, Gustavsen, Tsuyuki. Medical Cannabis Use in Canadians with Multiple Sclerosis. Multiple Sclerosis.Jan 27, 2022.
Learn something every day™ in your 
feed…
Our courses
CBD in Clinical Care V2
A Nationally Approved CME/CE Medical Marijuana Course V2
Cannabis Essentials CME/CE Bundle
New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.